Content » Preview

Clinical Report

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo for the SUPREME study group
DOI: 10.2340/00015555-3816

Preview of a paper in the copy-editing process

This article has been accepted for publication in Acta Dermato-Venereologica and is currently being edited and typeset. Readers should note that article shown below have been fully refereed, but have not been through the copy-editing and proof correction process. Only Abstract is possible to read. When this process is finalized the complete paper will be able to find.

Abstract

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score=0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Significance

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriatic disease. Secondary loss of response over time has been observed with biologic therapies for psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in patients with moderate-to-severe plaque psoriasis. After 24 weeks of treatment with secukinumab, the majority of patients achieved complete clearance and response was sustained to week 48, demonstrating the sustainability of response to secukinumab in patients with moderate-to-severe plaque psoriasis.

Supplementary content

Comments

Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.